Eli Lilly recruits university hospital CEO; Judge lightens kickback suit against Novartis; Auxilim launches generic Testim;

@FiercePharma: Top read on FP Marketing Weds: Men's Health Week or Low-T Week? Critics say awareness campaign is another pharma ploy. Article | Follow @FiercePharma

@TracyStaton: Trending at FiercePharmaMarketing: Do reps push drugs off-label? Study says yes. Does it work? Also yes. Story | Follow @TracyStaton

@EricPFierce: FDA says compounder making drugs under unsanitary conditions. More | Follow @EricPFierce

@CarlyHFierce: Merck's RotaTeq, Glaxo's Rotarix cut hospitalizations by up to 94%. FierceVaccines story | Follow @CarlyHFierce

@JustinHFierce: Some pet owners are becoming anti-vaxxers too, new trend sparks fears in vets over rabies surge. More from ABC | Follow @JustinHFierce

> Eli Lilly ($LLY) recruited Ora Pescovitz, former CEO of the University of Michigan Health System, to be a senior vice president, beginning in October. Report

> A New York federal judge whittled away at a False Claims Act lawsuit against Novartis ($NVS) and several specialty pharmacies over alleged kickbacks designed to boost sales of its leukemia drugs Gleevec and Tasigna. Report

> Auxilium Pharmaceuticals ($AUXL) said it partnered with Prasco to roll out an authorized generic version of its testosterone gel Testim. Report

> New long-term data on UCB's anti-inflammatory drug Cimzia showed improved outcomes in patients with spondyloarthritis. Release

> An Australian consumer watchdog group takes issue with the pricing on "premium versions" of common painkillers made by GlaxoSmithKline ($GSK) and Reckitt Benckiser. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: AbbVie to co-promote hep C diagnostic. Story | Follow @FierceMedDev

@StacyALawrence: Medtronic readies for 2015 drug-eluting balloon FDA approval. More | Follow @StacyALawrence

@MichaelGFierce: UCSB study: New silver nanoparticles dissolve if they don't hit their mark. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Mobile medical app brings laboratory testing to the home. Story | Follow @EmilyWFierce

> Withdrawn submissions are new focus for FDA med device review process. More

> FDA gives nod to Covidien's detachable tip microcatheter device. Story

> Survey: Med tech sales reps are out-earning biopharma. Article

Biotech News

@FierceBiotech: AstraZeneca extends global shopping spree with $232M asthma drug deal. More | Follow @FierceBiotech

@JohnCFierce: Kinda wonder why J&J didn't just buy Aduro if it likes its cancer drug work. Maybe that comes next, if it doesn't sour. | Follow @JohnCFierce

@DamianFierce: $GERN's up ~35% on hopes the FDA will release its full clinical hold on PhII cancer studies. News | Follow @DamianFierce

@EmilyMFierce: SARS enzyme finding could help advance MERS vaccine. FierceVaccines story | Follow @EmilyMFierce

> Is the biotech bubble back? Item

> Merck KGaA tackles hot immuno-oncology field in partnership with MorphoSys. Report

> J&J helps bankroll a $55M gamble on partner Aduro's PhIIb cancer drug study. News

Vaccines News

> Mortality dropped, but hospitalizations increased for some in '13-'14 flu season. Report

> Northwest Bio begins German vax trial as glioblastoma market poised to double. More

> Merck's RotaTeq, Glaxo's Rotarix cut hospitalizations by up to 94%. News

> Inovio shares dive on cervical cancer vax speculation. Item

> Dendreon CEO jumps ship as foundering company faces debt pileup. Article

Pharma Manufacturing News

> Teva CFO says company will close about three dozen plants. News

> Germany first in Europe to test database for defeating counterfeits. Item

> Supplier of unprotected foreign-made cancer drugs gets 15-month prison sentence. Report

> Merck sells salt plant in Lehrte to Schüssler Novachem. More

> Supplier of unprotected foreign-made cancer drugs gets 15-month prison sentence. Article

> Japan's Meiji snaps up Indian CMO Medreich for $290M. Story

And Finally... Rates of prediabetes in England are almost as high as those in the U.S., a new study found. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.